Robert Marx advises investors, growth companies and founders on M&A, venture capital and growth capital transactions as well as general corporate law matters.
His practice focuses on transaction and corporate law advice in connection with investments in growth-oriented companies, in particular in the areas of FinTech, e-commerce and software. He further advises growth companies on general corporate law issues, employee incentive schemes, equity and debt financing options and exit scenarios.
Robert studied law in Berlin. Before joining Osborne Clarke, he was an associate at an international law firm advising in the areas of venture capital, M&A and private equity.
Klima Energy Transition Fund
Osborne Clarke advises Klima Energy Transition Fund on Series B financing round of digital energy trading platform Enmacc, read more
Osborne Clarke advises Waverley Capital in Series B funding round at Endel, read more
Osborne Clarke advises eCAPITAL on financing round of Numbat, read more
Osborne Clarke advises VR Ventures on the sale of Penta, read more
Osborne Clarke advises Taxfix on its USD 220 million Series D Funding Round, read more
Sylphar NV and KaroPharma AB
Osborne Clarke advises Sylphar NV and Karo Pharma AB on purchase of Satin Naturel, read more
Haniel, eCapital and btov
Osborne Clarke advises Haniel, eCapital and btov on due diligence for Series A financing round of 1KOMMA5°, read more
Osborne Clarke advises Softr in USD 13.5 million Series A financing round, read more
Warburg Pincus and Hollyport Capital
Osborne Clarke advises Warburg Pincus and Hollyport Capital on Series D financing round of McMakler, read more
Osborne Clarke has advised DoorDash on USD 750 million Series B financing round of rapid delivery firm Flink SE, read more
Osborne Clarke advises Stenon in USD 20 million Series A financing, read more
Osborne Clarke advises Blickfeld on USD 31 million Series A funding, read more
Osborne Clarke advises N26 in billion-dollar funding round with top investors.
Osborne Clarke advises VR Ventures on financing round of CURE Finance, read more